US EditionPublished • loading... • Updated
GLP-1 Drugs Linked to Improved Survival in Colon Cancer Patients
Analysis of over 6,800 patients found GLP-1 receptor agonists reduced five-year colon cancer mortality from 37.1% to 15.5%, showing a significant survival benefit.
Summary by News Medical
3 Articles
3 Articles
GLP-1 drugs linked to improved survival in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar and weight.
·United States
Read Full Article
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking GLP-1 medications were less than half as likely to die withi…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
